Allarity Therapeutics Says FDA Granted Fast-Track Designation to Stenoparib; Shares Rise Pre-Bell
MT Newswires Live
Aug 26
Allarity Therapeutics (ALLR) said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.
Shares of the company rose more than 36% in recent Tuesday premarket activity.
The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.